文献速递白血病

治疗诱导突变驱动复发性急性淋巴细胞白血病的基因组格局

Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2020-01-01

该研究对103例诊断-复发-胚系三元组行全基因组测序,并对16例患者的208份连续样本行超深度测序,发现复发特异突变富集于12个药物反应相关基因。化疗诱导的耐药突变在部分儿童ALL复发中起驱动作用,并鉴定出两种新的复发特异突变特征。

要点

  • 复发特异突变富集于NR3C1、TP53、NT5C2等12个药物反应相关基因
  • 极早期复发源于预存耐药克隆,早期复发多为持续克隆治疗后获得耐药突变
  • 两种新复发特异突变特征见于27%复发ALL,致46%获得性耐药突变

核心结论

  • 化疗诱导的耐药突变促进部分儿童ALL复发。
  • 极早期复发来自预存耐药克隆,早期复发常为持续克隆在治疗中获得耐药突变的两步过程。

研究设计与样本

  • 对103例诊断-复发-胚系三元组行全基因组测序。
  • 对16例患者的208份连续样本行超深度测序。
  • 结合数学建模、突变特征分析及体外药物暴露实验。

主要发现

  • 复发特异体细胞变异富集于NR3C1、NR3C2、TP53、NT5C2、FPGS、CREBBP、MSH2、MSH6、PMS2、WHSC1、PRPS1和PRPS2共12个药物反应相关基因。
  • 上述变异在极早期复发(诊断后<9个月)组占17%,早期复发(9-36个月)组占65%,晚期复发(>36个月)组占32%。
  • 6例复发中观察到同一耐药基因多亚克隆突变的趋同进化,其中1例经单细胞测序证实。
  • 鉴定出两种新的复发特异突变特征,其中一种经体外药物暴露实验证实由巯嘌呤治疗引起;两者在2540份泛癌诊断样本和129例非ALL复发中均未出现。
  • 新突变特征见于27%的复发ALL,并导致NT5C2、PRPS1、NR3C1和TP53中46%的获得性耐药突变。

临床怎么用

  • 对复发ALL应关注药物反应相关基因的复发特异突变及新突变特征。
  • 极早期与早期复发的耐药机制不同,提示需按复发时间分层理解耐药来源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To study the mechanisms of relapse in acute lymphoblastic leukemia (ALL), we performed whole-genome sequencing of 103 diagnosis-relapse-germline trios and ultra-deep sequencing of 208 serial samples in 16 patients. Relapse-specific somatic alterations were enriched in 12 genes (NR3C1, NR3C2, TP53, NT5C2, FPGS, CREBBP, MSH2, MSH6, PMS2, WHSC1, PRPS1, and PRPS2) involved in drug response. Their prevalence was 17% in very early relapse (<9 months from diagnosis), 65% in early relapse (9-36 months), and 32% in late relapse (>36 months) groups. Convergent evolution, in which multiple subclones harbor mutations in the same drug resistance gene, was observed in 6 relapses and confirmed by single-cell sequencing in 1 case. Mathematical modeling and mutational signature analysis indicated that early relapse resistance acquisition was frequently a 2-step process in which a persistent clone survived initial therapy and later acquired bona fide resistance mutations during therapy. In contrast, very early relapses arose from preexisting resistant clone(s). Two novel relapse-specific mutational signatures, one of which was caused by thiopurine treatment based on in vitro drug exposure experiments, were identified in early and late relapses but were absent from 2540 pan-cancer diagnosis samples and 129 non-ALL relapses. The novel signatures were detected in 27% of relapsed ALLs and were responsible for 46% of acquired resistance mutations in NT5C2, PRPS1, NR3C1, and TP53. These results suggest that chemotherapy-induced drug resistance mutations facilitate a subset of pediatric ALL relapses.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood. 2020. PMID: 31697823. doi:10.1182/blood.2019002220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。